130,625 Shares in Kamada Ltd. (NASDAQ:KMDA) Acquired by Huntleigh Advisors Inc.

Huntleigh Advisors Inc. acquired a new stake in Kamada Ltd. (NASDAQ:KMDA - Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 130,625 shares of the biotechnology company's stock, valued at approximately $863,000. Huntleigh Advisors Inc. owned approximately 0.23% of Kamada at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Aristides Capital LLC boosted its stake in Kamada by 12.1% during the fourth quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company's stock worth $387,000 after buying an additional 6,850 shares during the last quarter. Geode Capital Management LLC grew its holdings in Kamada by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company's stock worth $178,000 after acquiring an additional 1,549 shares in the last quarter. NewEdge Advisors LLC lifted its position in shares of Kamada by 54.2% during the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company's stock worth $143,000 after purchasing an additional 8,260 shares during the last quarter. Finally, JPMorgan Chase & Co. purchased a new stake in shares of Kamada during the 4th quarter worth $67,000. Hedge funds and other institutional investors own 20.38% of the company's stock.

Kamada Stock Up 0.2%

NASDAQ:KMDA traded up $0.02 during midday trading on Friday, reaching $7.76. The stock had a trading volume of 23,331 shares, compared to its average volume of 96,622. The stock has a market cap of $446.05 million, a P/E ratio of 26.74, a P/E/G ratio of 0.96 and a beta of 0.96. Kamada Ltd. has a 12-month low of $5.08 and a 12-month high of $9.16. The firm has a fifty day simple moving average of $7.03 and a two-hundred day simple moving average of $6.89.

Kamada (NASDAQ:KMDA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.07. Kamada had a net margin of 9.60% and a return on equity of 6.31%. The business had revenue of $44.02 million for the quarter, compared to analyst estimates of $154.06 million. On average, sell-side analysts anticipate that Kamada Ltd. will post 0.23 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

KMDA has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $11.00 price target on shares of Kamada in a report on Thursday, March 6th. Wall Street Zen raised shares of Kamada from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, May 21st. Benchmark reaffirmed a "buy" rating and issued a $15.00 target price on shares of Kamada in a report on Thursday, May 15th. Finally, Sidoti upgraded Kamada to a "hold" rating in a research report on Thursday, May 8th.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.